Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/25/2025

Safety of Adding Flibanserin to Medication Regimens

Clinical Efficacy Expectations

  • Flibanserin results in approximately 0.5 additional satisfying sexual events per month compared to placebo, according to the Journal of the National Comprehensive Cancer Network 1
  • The American College of Obstetricians and Gynecologists recommends flibanserin as a first-line option for premenopausal women with HSDD, despite its limited efficacy 3

Dosing and Monitoring

  • The American College of Obstetricians and Gynecologists recommends initiating flibanserin at 100 mg at bedtime, which is the FDA-approved dose for premenopausal women with HSDD 3

REFERENCES

1

survivorship, version 2.2017, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

2

Flibanserin for Hypoactive Sexual Desire Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025